Tandem Diabetes Care logo

Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, February 22nd. Analysts expect the company to announce earnings of $0.20 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

TNDM stock opened at $115.11 on Tuesday. The company has a market capitalization of $7.31 billion, a price-to-earnings ratio of 396.93 and a beta of 0.40. Tandem Diabetes Care has a 1-year low of $76.19 and a 1-year high of $155.86. The business has a 50 day simple moving average of $131.54 and a two-hundred day simple moving average of $126.21. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.31 and a quick ratio of 5.76.

Several analysts recently weighed in on the company. Piper Sandler increased their price target on Tandem Diabetes Care from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, December 6th. Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $137.00 to $160.00 in a research note on Wednesday, January 19th. SVB Leerink increased their price target on Tandem Diabetes Care from $135.00 to $140.00 and gave the stock a “market perform” rating in a research report on Thursday, November 4th. Lake Street Capital increased their price target on Tandem Diabetes Care from $165.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, December 7th. Finally, Raymond James raised their price objective on Tandem Diabetes Care from $120.00 to $138.00 and gave the company an “outperform” rating in a research report on Thursday, November 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $144.44.

(Ad)

Don’t be fooled by other guides showing off their once-in-a-lifetime or horribly out of date trade examples.

“Options Basics” will give you real world and real time trade examples to help you grow your account while minimizing risk!

In other Tandem Diabetes Care news, EVP David B. Berger sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 1st. The stock was sold at an average price of $128.44, for a total value of $128,440.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rebecca B. Robertson sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $117.97, for a total value of $176,955.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,478 shares of company stock valued at $3,157,302. Company insiders own 4.80% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Featured Stories

Earnings History for Tandem Diabetes Care (NASDAQ:TNDM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Tandem Diabetes Care right now?

Before you consider Tandem Diabetes Care, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tandem Diabetes Care wasn’t on the list.

While Tandem Diabetes Care currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 

More Info

By Betty C. Giordano

Welcome to my site. My name is Betty C. Giordano and I am a blogger of everything related to mobile, news, events and reality in general. I hope you enjoy reading my content.

Leave a Reply